Get started
Author

Amit S. Khot

Observed names: A Khot, A. Khot, A.S. Khot, Ami t S Khot, Amit Khot, Amit S Khot, Khot, Amit
ORCID: 0000-0002-9210-5373
Observed ORCID: 0000-0002-9210-5373
OpenAlex ID: A5018838899
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
2018 · Youn H Kim, Martine Bagot, et al. · The Lancet Oncology · 669
PDF
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
2013 · David S. Ritchie, Paul J. Neeson, et al. · Molecular Therapy · 443
PDF
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
2014 · S Kamel, L Horton, et al. · Leukemia · 231
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
2014 · Charlotte F. M. Hughes, Amit Khot, et al. · Blood · 228
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
2019 · Amit Khot, Natalie Brajanovski, et al. · Cancer Discovery · 196
Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma
2016 · P. Blombery, E. R. Thompson, et al. · Haematologica · 150
PDF
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
2016 · Jaclyn Quin, Keefe T. Chan, et al. · Oncotarget · 107
PDF
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route
2011 · Claire E. Dearden, Amit Khot, et al. · Blood · 96
PDF
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
2023 · Adrian Minson, Nada Hamad, et al. · Blood · 82
A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma ( NPI ‐0052‐107): final study results
2017 · Andrew Spencer, Simon Harrison, et al. · British Journal of Haematology · 73
PDF
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
2019 · Timothy A. Brighton, Amit Khot, et al. · Clinical Cancer Research · 71
DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
2020 · Rakesh Popat, Ajay Nooka, et al. · Blood · 47
Panobinostat in lymphoid and myeloid malignancies
2013 · Amit Khot, Michael Dickinson, et al. · Expert Opinion on Investigational Drugs · 42
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
2023 · Thomas E Lew, Adrian Minson, et al. · The Lancet Haematology · 39
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
2020 · Ajay K. Nooka, Keith Stockerl-Goldstein, et al. · Journal of Clinical Oncology · 36
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial
2022 · Abby Douglas, Karin Thursky, et al. · The Lancet Haematology · 29
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
2024 · Michelle A. Neller, George R. Ambalathingal, et al. · Nature Communications · 25
PDF
Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
2020 · Ella R. Thompson, Tamia Nguyen, et al. · Haematologica · 25
PDF
Romidepsin for Cutaneous T-Cell Lymphoma
2013 · H Miles Prince, Michael Dickinson, et al. · Future Oncology · 23
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
2024 · Matthew J. Rees, Aytaj Mammadzadeh, et al. · Blood Cancer Journal · 21
PDF
Prehabilitation in high-risk patients scheduled for major abdominal cancer surgery: a feasibility study
2022 · Jamie L. Waterland, Hilmy Ismail, et al. · Perioperative Medicine · 21
PDF
Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study
2017 · Youn H. Kim, Martine Bagot, et al. · Blood · 18
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy
2010 · Rebecca Howman, Arti Thakerer, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 18
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy
2025 · Kezia Gitareja, Shalini S. Chelliah, et al. · Cancers · 17
PDF
Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation
2021 · Kim H. Tay, Monica A. Slavin, et al. · Internal Medicine Journal · 16
Works count: 151
Citation count: 3,100
H-index: 21
I10-index: 45
Year
Topic
Type